Slingshot members are tracking this event:

Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA (pemetrexed) and CYRAMZA (ramucirumab) with Merck's KEYTRUDA (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 05, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Alimta, Pemetrexed, Cyramza, Ramucirumab, Keytruda, Pembrolizumab, Nsclc